On the State and Federal level, legislation is passed every year that affects our access to healthcare as well as the quality and affordability of our health care. We fight for legislation that will improve the health of all adults and children across the country.
The Patient, Consumer, and Public Health Coalition, we strongly support H.R. 1150, the Preservation of Antibiotics for Medical Treatment Act. The Act would help to preserve the effectiveness of antimicrobials used to treat diseases in both animals and humans.
The Patient, Consumer, and Public Health Coalition strongly opposes the Preventing Regulatory Overreach To Enhance Care Technology (PROECT) Act of 2014. The Act, as drafted, would have the harmful consequence of exempting so-called “health software” and “clinical software” devices from FDA oversight. Also, the Act is premature. Congress is awaiting a study commissioned in 2012 to guide policymakers on this very issue.
As members of the Patient, Consumer, and Public Health Coalition, we strongly oppose the Preventing Regulatory Overrreach To Enhance Care Technology (PROTECT) Act of 2014. The Act, as drafted, would have the harmful consequence of exempting so-called “health software” and “clinical software” devices from FDA oversight. Also, the Act is premature. Congress is awaiting a study commissioned in 2012 to guide policymakers on this very issue.
We strongly oppose H.R. 3303, the SOFTWARE Act of 2013. The Act, as drafted, would have the harmful consequence of exempting so-called “health software” and “clinical software” devices from FDA oversight. Also, the Act is premature. Congress is awaiting a study commissioned in 2012 to guide lawmakers on this very issue.
Letter to Ranking Member Waxmen of Opposition to H.R. 3303, the SOFTWARE Act of 2013 Read More »
The Patient, Consumer, and Public Health Coalition conditionally supports the draft guidance “Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act” (FD&C) because it clarifies FDA enforcement actions that can be taken against individuals or firms that illegally make drugs under the banner of traditional compounding.
We are writing to thank you for your dedication to patients and consumers through your work to strengthen safeguards for all medical products sold in the United States. Your continued efforts through the years, including your recent letter to the FDA Commissioner, is needed now more than ever to help preserve the public health mission of the FDA.
We oppose H.J. Res 77 and any other efforts to single out the Food and Drug Administration for funding. Our organizations represent millions of patients, consumers, health professionals, and scientists who strongly support the work of the FDA and urge Congress to provide the level of appropriations the agency needs throughout FY 2014.
Letter to House Leaders in Opposition to H.J. Res 77 Read More »
We strongly support the FDA’s ban on importing drugs manufactured at Ranbaxy Laboratories, Ltd.’s facility in Mohali, India. The company’s facility is not complying with current good manufacturing practices (cGMP), which are the main regulatory safeguard to ensure drug manufacturing quality.
We re very supportive of the Patient Protection and Affordable Care Act (ACA). We were extremely disappointed that the Hatch-Klobuchar amendment (S. Amdt. 297 to S. Con. Res. 8 ) to repeal the 2.3% excise tax on medical devices was overwhelmingly supported. Thank you very much for your important vote against the amendment. We are writing to ask for a meeting with your staff to discuss this issue.
Letter to Key U.S. Senators in Support of Funding for the Affordable Care Act Read More »
The Coalition writes to Congresswoman DeLauro to strongly support the “Healthy Families Act”, which creates a national standard for paid sick days.
Letter to Congresswoman Rosa DeLauro in Support of the “Healthy Families Act” Read More »
